- Home
- QURE
QURE
uniQure N.V.
as 10-22-2024 4:00pm EST
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
| Founded: | 1998 | Country: | Netherlands |
| Employees: | N/A | City: | AMSTERDAM |
| Market Cap: | 432.6M | IPO Year: | 2007 |
| Target Price: | $19.50 | AVG Volume (30 days): | 846.7K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.73 - $11.35 | Next Earning Date: | 11-05-2024 |
| Revenue: | $27,707,000 | Revenue Growth: | -75.25% |
| Revenue Growth (this year): | 187.6% | Revenue Growth (next year): | 51.90% |
Latest uniQure N.V. News
QURE Breaking Stock News: Dive into QURE Ticker-Specific Updates for Smart Investing
GuruFocus.com
5 days ago
State Street Corp's Strategic Reduction in uniQure NV Holdings
GlobeNewswire
8 days ago
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
GlobeNewswire
8 days ago
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
Zacks
14 days ago
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
MT Newswires
a month ago
UniQure's Gets Orphan Drug Designation From FDA for Fabry Disease Treatment
GlobeNewswire
a month ago
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
Simply Wall St.
a month ago
uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago
GlobeNewswire
2 months ago
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
Compare QURE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QURE uniQure N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.